Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the companyâs transformative, high precision ophthalmic delivery platform. Eyenoviaâs pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases. Source
No articles found.
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage co...
AVROBIO, Inc., a leader in lentiviral-based gen...
Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental...
Pluristem Therapeutics Inc. is a clinical-stage...
HMS advances the healthcare system by helping healthcare organizations reduce cost...
HMS advances the healthcare system by helping h...
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, le...
Intra-Cellular Therapies is a biopharmaceutical...
Aldeyra Therapeutics is a biotechnology company devoted to developing and commerci...
Aldeyra Therapeutics is a biotechnology company...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Join the National Investor Network and get the latest information with your interests in mind.